Dare Bioscience Inc. (NASDAQ:DARE) price on Wednesday, August 25, rose 3.64% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.71.
A look at the stock’s price movement, the close in the last trading session was $1.65, moving within a range at $1.65 and $1.76. The beta value (5-Year monthly) was 1.50. Turning to its 52-week performance, $3.85 and $0.94 were the 52-week high and 52-week low respectively. Overall, DARE moved 20.42% over the past month.
Dare Bioscience Inc.’s market cap currently stands at around $114.40 million, with investors looking forward to this quarter’s earnings report slated for Nov 10, 2021 – Nov 15, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.16, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.68 and about -$0.7 for fiscal year 2022. Per the data, EPS growth is expected to be 25.30% for 2021 and -2.90% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that DARE is a 50% Buy. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend DARE as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
DARE’s current price about 8.30% and 9.06% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 58.45, while 7-day volatility ratio is 6.46% and 7.12% in the 30-day chart. Further, Dare Bioscience Inc. (DARE) has a beta value of 1.69, and an average true range (ATR) of 0.11. Analysts have given the company’s stock an average 52-week price target of $5.50, forecast between a low of $3.00 and high of $11.00. Looking at the price targets, the low is -75.44% off current price level while to achieve the yearly target high, price needs to move -543.27%. Nonetheless, investors will most likely welcome a -133.92% jump to $4.00 which is the analysts’ median price.
In the market, a comparison of Dare Bioscience Inc. (DARE) and its peers suggest the former has performed considerably stronger. Data shows DARE’s intraday price has changed 3.64% in last session and 56.88% over the past year. Comparatively, Clovis Oncology Inc. (CLVS) has moved 0.87% on the day and only -9.23% in the past 12 months. Looking at another peer, we see that Madrigal Pharmaceuticals Inc. (MDGL) price has gained 0.26% on the day. However, the stock is -22.30% off its price a year ago. Moreover, Seagen Inc. (SGEN) is also up 1.12% in trading on the day while keeping a an uptrend of 9.64% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.22% and 0.11% respectively in the last trading.
If we refocus on Dare Bioscience Inc. (NASDAQ:DARE), historical trading data shows that trading volumes averaged 9.17 million over the past 3 months. The company’s latest data on shares outstanding shows there are 50.44 million shares.
The 5.57% of Dare Bioscience Inc.’s shares are in the hands of company insiders while institutional holders own 5.00% of the company’s shares. Current price change has pushed the stock 27.61% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DARE stock continues to rise going into the next quarter.